TF and dry eye syndrome: The development of new drugs like diquafosol sodium, rebamipide, and lacritin—specifically targeting the mucus component of the TF—warrants gains of further understanding of the contribution of mucins to the functionality of the TF and to the better treatment of the diverse types of dry eye syndrome.